Article Text

Download PDFPDF
Tumour lysis syndrome following eribulin for metastatic uterine leiomyosarcoma
  1. Cindy Pabon1,
  2. Ashwini K Esnakula2 and
  3. Karen Daily3
  1. 1 College of Medicine, University of Florida, Gainesville, Florida, USA
  2. 2 Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, Florida, USA
  3. 3 Department of Hematology and Oncology, University of Florida, Gainesville, Florida, USA
  1. Correspondence to Dr Karen Daily, karen.daily{at}


A middle-aged woman with a history of leiomyosarcoma of the uterus treated with surgery and adjuvant chemotherapy suffered a bulky metastatic recurrence 1 year later. She elected treatment with palliative eribulin, presenting with acute renal failure and electrolyte abnormalities consistent with tumour lysis syndrome on cycle 1 day 8. Despite aggressive supportive care and treatment including intravenous hydration, bicarbonate and rasburicase, she continued to decline, ultimately foregoing haemodialysis in favour of palliative care and passed away in the hospital.

  • gynecological cancer
  • unwanted effects / adverse reactions
  • chemotherapy

Statistics from


  • Patient consent for publication Not required.

  • Contributors CM: reviewed the electronic medical record information on our patient and relevant literature and wrote the first draft. AKE: prepared the pathology figure. KD: edited, revised and submitted the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.